Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Scientists from the U.K. may have identified several more environmental causes for cancer after evaluating genetic data of over 12,000 cancer patients from the NHS files.
Biotech companies are facing sharp declines in stock prices, while venture capital and private equity are experiencing increases. BDO Life Sciences’ Lance Minor sat down BioSpace’s Gail Dutton.
Rita Levi-Montalcini is perhaps best known for her award-winning work in the discovery and isolation of Nerve Growth Factor (NGF) in 1956. Here’s more about her.
Bristol Myers Squibb will hear from the FDA on April 28 about Mavacamten, while Supernus, Axsome, Coherus, Hutchmed and Incyte also await the fate of their respective drug candidates.
Today, Astellas announced that after evaluating its gene therapy for patients with X-linked Myotubular Myopathy, it revised its eligible treatment population and any likely future product label.
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
Louisiana Attorney General Jeff Garland sued UnitedHealth Group over Medicaid fraud. In a lawsuit filed earlier this week, Garland alleged the insurance company overinflated drug charges.
Biogen has withdrawn its Marketing Authorization Application (MAA) for European approval of Aduhelm after regulators hinted data was not strong enough to support potential approval.
As Omicron dominates the COVID-19 landscape, scientists are urging the FDA to reconsider how the agency defines immune responses.
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
Faron Pharmaceuticals announced a new analysis that estimates 100% overall survival at 12-months for patients who experienced clinical benefit following treatment with bexmarilimab.
Most employers are well aware of the devastating effects the pandemic has had on employee retention. Read on to find out how long you can expect your staff to stay and how to keep them.